GSK plc (NYSE:GSK) Q1 2024 Earnings Call Transcript

Tony Wood: Yes. Just to add to that, reversible, transient and manageable. Those are the three words to think about, and I’ll point you to a first-line ISS study interface that was published in the European Myeloma Network in April, if you want to get a sense of what sits behind those three words.

Emma Walmsley: Thank you.

Nick Stone: In the spirit of keeping this to time I said, I think we will have to close the call there. So, Emma, if there is anything you want to just add in terms of closing comments?

Emma Walmsley: No. Just to repeat, a very strong start to 2024, another quarter of excellent performance and physically continued pipeline progress. And this whole team and all that support remain very strongly committed to delivering our potential and more. So we look forward to catching up with many of you on calls in the coming days and over the months ahead.